PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12133029-1	2002	PURPOSE: To determine the association between the early rise in serum creatinine levels associated with the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and the long-term renoprotective properties of these drugs in patients with chronic renal insufficiency.	Creatinine	70-80	angiotensin I converting enzyme	Homo sapiens	146-149	
12133029-4	2002	In fact, patients who have the most advanced renal insufficiency at baseline are the ones who show the maximum slowing of the disease progression, but these patients are also more likely to show an early rise in serum creatinine levels after ACE inhibitor therapy.	Creatinine	218-228	angiotensin I converting enzyme	Homo sapiens	242-245	
12133029-7	2002	One of the main reasons for this underutilization of ACE inhibitors in patients with heart failure is the underlying renal insufficiency or the rise in serum creatinine level after initiation of therapy with an ACE inhibitor.	Creatinine	158-168	angiotensin I converting enzyme	Homo sapiens	53-56	
12133029-7	2002	One of the main reasons for this underutilization of ACE inhibitors in patients with heart failure is the underlying renal insufficiency or the rise in serum creatinine level after initiation of therapy with an ACE inhibitor.	Creatinine	158-168	angiotensin I converting enzyme	Homo sapiens	211-214	
12133029-17	2002	RESULTS: Patients with preexisting chronic renal insufficiency who achieved their blood pressure control goals were likely to demonstrate an early rise in serum creatinine levels, approximately 25% above the baseline (approximately 1.7 mg/dL) after initiation of ACE inhibitor or ARB therapy.	Creatinine	161-171	angiotensin I converting enzyme	Homo sapiens	263-266	
12133029-25	2002	Serum creatinine levels in these patients sharply increased (by approximately 75% above baseline) in the 2 weeks after the initiation of therapy with an ACE inhibitor, followed by an even sharper increase (another approximately 150%) during the subsequent 2 weeks.	Creatinine	6-16	angiotensin I converting enzyme	Homo sapiens	153-156	
12133029-26	2002	Patients with chronic renal insufficiency (serum creatinine>1.5 mg/dL) who received therapy with ACE inhibitors had about a five times higher risk of developing hyperkalemia than those with normal renal function, whereas presence of heart failure increased the risk of hyperkalemia by about three times over those without heart failure.	Creatinine	49-59	angiotensin I converting enzyme	Homo sapiens	100-103	
12133029-28	2002	CONCLUSION: The authors conclude that, in patients with renal insufficiency (serum creatinine>1.4 mg/dL) treated with ACE inhibitors, there is a strong association between early (within the first 2 months) and moderate (not exceeding 30% over baseline) rise in serum creatinine and slowing of the renal disease progression in the long run.	Creatinine	83-93	angiotensin I converting enzyme	Homo sapiens	121-124	
12133029-28	2002	CONCLUSION: The authors conclude that, in patients with renal insufficiency (serum creatinine>1.4 mg/dL) treated with ACE inhibitors, there is a strong association between early (within the first 2 months) and moderate (not exceeding 30% over baseline) rise in serum creatinine and slowing of the renal disease progression in the long run.	Creatinine	270-280	angiotensin I converting enzyme	Homo sapiens	121-124